摘要
目的:探讨玻璃粘连蛋白血清学表达与乳腺癌早期诊断的相关性。方法:采用酶联免疫吸附试验(ELISA)定量测定62例乳腺癌(0-Ⅰ期癌22例,Ⅱ-Ⅲ期癌40例)和8例乳腺良性病变患者血清玻璃粘连蛋白水平,分析玻璃粘连蛋白表达在良性与各期乳腺癌中的变化规律,同时比较CA153、CA125、CEA的表达情况。结果:0-Ⅰ期乳腺癌组血清玻璃粘连蛋白的表达水平(231.45±30.54μg/m L)显著高于良性对照组(197.84±24.31μg/m L)和Ⅱ-Ⅲ期乳腺癌组(209.34±31.25μg/m L),差异均有统计学意义(P<0.01);玻璃粘连蛋白血清表达水平与乳腺癌组织学分级、年龄、肿瘤大小、月经状况、ER、PR、Her-2及Ki-67表达无关(P>0.05);而血清CA153、CA125、CEA表达水平随着临床分期升高而升高,其中CA153的表达存在统计学差异(P<0.05)。结论:血清玻璃粘连蛋白水平在早期阶段乳腺癌(0-Ⅰ期)显著高于良性和中期(Ⅱ-Ⅲ期)乳腺癌患者,提示玻璃粘连蛋白可能是一项有潜力的乳腺癌早期诊断指标,而血清CA153、CA125、CEA表达则主要与乳腺癌病情发展相关。
Objective： To explores the correlation between the vitronectin serological expression and the early diagnosis of breast cancer. Methods： The serum vitronectin levels were detected and analyzed in 62 patients with breast cancer（22 cases of stages 0-Ⅰ, 40 cases of stages Ⅱ-Ⅲ） and 8 patients with benign disease of breast by ELISA. The expression of serum vitronectin and classical markers of breast cancer（CA153, CA125, CEA） were compared in each group of patients. Results： Serum vitronectin level in stage 0- Ⅰ breast cancer group（231.45± 30.54μg/mL） was significantly higher than the benign control group（197.84±24.31 μg/mL）（P〈0.01） and stage Ⅱ-Ⅲ group（209.34±31.25 μg/mL）（P〈0.01）. The serum vitronectin level had no correlation with patients age, tumor size, menopausal status, ER, PR, Her-2 and Ki-67 expression（P〈0.05）. With the phase increasing, the levels of serum CA153, CA125 and CEA increased, and CA153 has the statistical significance among them（P〈0.05）. Con- clusion： The serum vitronectin level was specific highly expressed in patients with early breast cancer（stage 0-I group） than the other groups and might be a potential early diagnosis index for breast cancer, while the classical serum markers（CA153, CA125, CEA） would have a close relationship with the progression of breast cancer.
出处
《生物技术通讯》
CAS
2015年第2期215-218,共4页
Letters in Biotechnology
